TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis.
Andrew M BrownIhab KassabMarco MassaniWhitney TownsendAmit G SingalCigdem SoydalLaura Moreno-LunaLewis R RobertsVincent L ChenNeehar D ParikhPublished in: Cancer medicine (2022)
Current data suggest TARE provides significantly longer TTP than TACE, although the two treatments do not significantly differ in terms of OS. Given limitations of the current data, there is rationale for prospective studies comparing these modalities.